Lv61
1960 积分 2022-12-19 加入
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
3天前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
3天前
已完结
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma
17天前
已完结
Teclistamab for relapsed refractory multiple myeloma patients on dialysis
18天前
已完结
Predicting the Future for AL Amyloidosis Patients With Cardiac Involvement
19天前
已完结
Multiple myeloma
24天前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
2个月前
已完结
AL Amyloidosis
3个月前
已完结
Plasma cell leukemia: Retrospective review of cases at Monter Cancer Center/Northwell Health Cancer Institute, 2014-2019
3个月前
已完结
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
3个月前
已完结
皖公网安备34019202002308
